TREAT PTSD Act
- Sponsor
- Rep. Perry, Scott [R-PA-10]
- Committees
- Veterans' Affairs Committee (primary)
- Last action
- Mar 27, 2025
Bottom line
The TREAT PTSD Act mandates the VA and DoD to provide stellate ganglion block as a treatment option for veterans and service members with PTSD, aiming to expand access to this therapy.
What it actually does
This bill directs the Department of Veterans Affairs (VA) and the Department of Defense (DoD) to furnish stellate ganglion block (SGB) to veterans and active-duty service members diagnosed with post-traumatic stress disorder (PTSD) who elect to receive the treatment. It also mandates an update to the joint VA/DoD Clinical Practice Guideline for PTSD to reflect SGB as a therapy option and include clinical indicators and contraindicators. The provisions related to furnishing SGB take effect 180 days after enactment.
Proponents argue
Proponents argue that SGB is a promising and effective treatment for PTSD that can provide rapid relief from symptoms, improve quality of life, and potentially reduce suicide risk among veterans and service members. They contend that mandating its provision ensures that those who could benefit from this therapy have access to it, especially if it is not yet widely available or consistently covered through existing healthcare pathways.
Opponents contend
Opponents might raise concerns that mandating a specific medical treatment through legislation could bypass established clinical review processes and potentially lead to the widespread adoption of a therapy before its long-term efficacy and safety are fully understood across diverse patient populations. They may argue that clinical decisions should remain primarily with healthcare providers, guided by evolving medical evidence, rather than being legislatively prescribed.
The bill is short and clearly written, making it accessible for a quick read and easy to understand its core directives.
Section 2(a)
Provision of Stellate Ganglion Block to Veterans
This provision amends Title 38 of the U.S. Code to require the Secretary of Veterans Affairs to provide stellate ganglion block (SGB) to any veteran who is enrolled in the VA patient enrollment system, has a PTSD diagnosis, and chooses to receive SGB after being informed of its risks and benefits. The VA can furnish this care either through its own medical facilities or through external healthcare providers.
Supporters argue
Supporters argue this provision is crucial for ensuring veterans suffering from PTSD have access to SGB, which many believe offers significant relief and improves their quality of life, potentially reducing the burden of PTSD symptoms.
Critics contend
Critics may argue that mandating a specific treatment could strain VA resources, potentially diverting funds or personnel from other critical mental health services, and might not allow for sufficient clinical discretion in treatment plans.
Tradeoffs
The provision balances the desire to provide a specific, potentially effective treatment with the need for the VA to manage its resources and maintain clinical autonomy in treatment decisions.
Section 2(b)
Provision of Stellate Ganglion Block to Members of the Armed Forces
This section amends Title 10 of the U.S. Code to require the Secretary of Defense to provide stellate ganglion block (SGB) to any active-duty or reserve service member who is enrolled in the TRICARE program, has a PTSD diagnosis, and chooses to receive SGB after being informed of its risks and benefits. The DoD can furnish this care through its medical facilities or through qualified healthcare providers participating in TRICARE.
Section 2(c)
Update of Joint Clinical Practice Guideline
This provision directs the Secretaries of Veterans Affairs and Defense to update their joint "VA/DOD Clinical Practice Guideline (CPG) for the Management of PTSD" within 180 days of the bill's enactment. The update must ensure the guideline reflects SGB as an available therapy option and includes information on its clinical indicators (when it's appropriate) and contraindicators (when it's not appropriate). The Secretaries must notify Congress once the guideline is updated.